These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 20233577

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
    Okazaki H, Hirata D, Kamimura T, Sato H, Iwamoto M, Yoshio T, Masuyama J, Fujimura A, Kobayashi E, Kano S, Minota S.
    J Rheumatol; 2002 Apr; 29(4):707-16. PubMed ID: 11950011
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.
    Chiba K.
    Pharmacol Ther; 2005 Dec; 108(3):308-19. PubMed ID: 15951022
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The lymphocyte migration inhibitor FTY720 attenuates experimental hypertensive nephropathy.
    Krämer S, Binder E, Loof T, Wang-Rosenke Y, Martini S, Khadzhynov D, Budde K, Neumayer HH, Peters H.
    Am J Physiol Renal Physiol; 2009 Jul; 297(1):F218-27. PubMed ID: 19439518
    [Abstract] [Full Text] [Related]

  • 8. Sphingosine-1-phosphate analogue FTY720 causes lymphocyte redistribution and hypercholesterolemia in ApoE-deficient mice.
    Klingenberg R, Nofer JR, Rudling M, Bea F, Blessing E, Preusch M, Grone HJ, Katus HA, Hansson GK, Dengler TJ.
    Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2392-9. PubMed ID: 17761943
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs.
    Hofmann M, Brinkmann V, Zerwes HG.
    Int Immunopharmacol; 2006 Dec 20; 6(13-14):1902-10. PubMed ID: 17161343
    [Abstract] [Full Text] [Related]

  • 11. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.
    Mehling M, Brinkmann V, Antel J, Bar-Or A, Goebels N, Vedrine C, Kristofic C, Kuhle J, Lindberg RL, Kappos L.
    Neurology; 2008 Oct 14; 71(16):1261-7. PubMed ID: 18852441
    [Abstract] [Full Text] [Related]

  • 12. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice.
    Nofer JR, Bot M, Brodde M, Taylor PJ, Salm P, Brinkmann V, van Berkel T, Assmann G, Biessen EA.
    Circulation; 2007 Jan 30; 115(4):501-8. PubMed ID: 17242282
    [Abstract] [Full Text] [Related]

  • 13. FTY720 for treatment of ischemia-reperfusion injury following complete renal ischemia; impact on long-term survival and T-lymphocyte tissue infiltration.
    Kaudel CP, Frink M, Schmiddem U, Probst C, Bergmann S, Krettek C, Klempnauer J, van Griensven M, Winkler M.
    Transplant Proc; 2007 Mar 30; 39(2):499-502. PubMed ID: 17362767
    [Abstract] [Full Text] [Related]

  • 14. FTY720 suppresses CD4+CD44highCD62L- effector memory T cell-mediated colitis.
    Fujii R, Kanai T, Nemoto Y, Makita S, Oshima S, Okamoto R, Tsuchiya K, Totsuka T, Watanabe M.
    Am J Physiol Gastrointest Liver Physiol; 2006 Aug 30; 291(2):G267-74. PubMed ID: 16574986
    [Abstract] [Full Text] [Related]

  • 15. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
    Mehling M, Lindberg R, Raulf F, Kuhle J, Hess C, Kappos L, Brinkmann V.
    Neurology; 2010 Aug 03; 75(5):403-10. PubMed ID: 20592255
    [Abstract] [Full Text] [Related]

  • 16. Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models.
    Azuma H, Takahara S, Ichimaru N, Wang JD, Itoh Y, Otsuki Y, Morimoto J, Fukui R, Hoshiga M, Ishihara T, Nonomura N, Suzuki S, Okuyama A, Katsuoka Y.
    Cancer Res; 2002 Mar 01; 62(5):1410-9. PubMed ID: 11888913
    [Abstract] [Full Text] [Related]

  • 17. FTY720 application following isolated warm liver ischemia improves long-term survival and organ protection in a mouse model.
    Kaudel CP, Frink M, van Griensven M, Schmiddem U, Probst C, Bergmann S, Krettek C, Klempnauer J, Winkler M.
    Transplant Proc; 2007 Mar 01; 39(2):493-8. PubMed ID: 17362766
    [Abstract] [Full Text] [Related]

  • 18. Sphingosine-1-phosphate and FTY720 as anti-atherosclerotic lipid compounds.
    Tölle M, Levkau B, Kleuser B, van der Giet M.
    Eur J Clin Invest; 2007 Mar 01; 37(3):171-9. PubMed ID: 17359484
    [Abstract] [Full Text] [Related]

  • 19. Transient T cell accumulation in lymph nodes and sustained lymphopenia in mice treated with FTY720.
    Morris MA, Gibb DR, Picard F, Brinkmann V, Straume M, Ley K.
    Eur J Immunol; 2005 Dec 01; 35(12):3570-80. PubMed ID: 16285007
    [Abstract] [Full Text] [Related]

  • 20. Effect of anti-CD134L mAb and CTLA4Ig on ConA-induced proliferation, Th cytokine secretion, and anti-dsDNA antibody production in spleen cells from lupus-prone BXSB mice.
    Zhou YB, Ye RG, Li YJ, Xie CM, Wu YH.
    Autoimmunity; 2008 Aug 01; 41(5):395-404. PubMed ID: 18568645
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.